Article
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Blood - 14 Apr 2016
Parker Wendy T, Yeung David T O, Yeoman Alexandra L, Altamura Haley K, Jamison Bronte A, Field Chani R, Hodgson J Graeme, Lustgarten Stephanie, Rivera Victor M, Hughes Timothy P, Branford Susan
Abstract excerpt
The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML). However, responses are variable, and causal baseline factors have not been well-studied. The type and number of low-level BCR-ABL1 mutations present after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.